Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Saxagliptin/Dapagliflozin FDC vs Individual Components
NCT02060201Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2014
- Primary completion
- May 2014
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of dapagliflozin + saxagliptin in type 2 diabetes mellitus (T2DM) (6 arms), sponsored by AstraZeneca. Primary endpoints: Maximum observed plasma concentration up to 15 days, Area under the concentration-time curve from time zero to the time of the last quantifiable concentration up to 15 days and 1 more. Started Feb 2014; status: completed.
02
Drugs
dapagliflozin + saxagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02060201.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02060201.